Bavarian Nordic begins Phase 1 clinical trial of MVA-BN® WEV vaccine
Category: #health  By Pankaj Singh  Date: 2019-10-10
  • share
  • Twitter
  • Facebook
  • LinkedIn

Bavarian Nordic begins Phase 1 clinical trial of MVA-BN® WEV vaccine

The trial will reportedly examine the safety, tolerability and immunogenicity of MVA-BN WEV

The U.S. is currently facing the worst outbreak of the Eastern equine encephalitis virus (EEEV). Over 30 cases were reported in 2019, which included 9 fatalities, majorly in the north-eastern regions of the country, where mosquitoes have been found to carry the virus.

Denmark-based biotechnology company Bavarian Nordic recently announced the commencement of the first-in-human trial of its prophylactic vaccine candidate, MVA-BN® WEV, for the prevention of equine encephalitis virus.

Reportedly funded by the U.S. Department of Defense Joint Project Manager for Chemical, Biological, Radiation and Nuclear Medicine (JPM CBRN Medical), the project is a multi-year agreement valued at $36 million that aims to formulate a vaccine against three different forms of the equine encephalitis virus – Eastern (EEEV), Venezuelan and (VEEV)Western (WEEV). Currently, there are no preventive vaccines available for the virus.

The Phase 1 trial will evidently analyze the safety, efficacy and tolerability of MVA-BN WEV in 45 healthy adults divided into three treatment groups which will be administered with different doses of the vaccine. It is estimated that promising results from the study will be achieved and available by 2020.

Sources familiar with the matter reported that a successful Phase 1 trial, based on demonstrating favorable safety and efficacy, could lead to additional funding beyond the initial USD 36 million contract award, to promote further clinical, preclinical development and manufacturing to obtain licensure in the U.S.

Bavarian Nordic President and CEO Paul Chaplin was reported saying that following the recent FDA approval of its smallpox vaccine, which was formulated in collaboration with numerous U.S. Government agencies and has become a vital part of the national stockpile, the company looks forward to advancing the new & innovative program and help realize the U.S. government’s goal to develop a wide range of medical countermeasures to protect U.S. citizens.

The occurrence of Triple E virus has significantly increased in US, highlighting the need to develop a vaccine to tackle the disease. To address the unmet medical needs, the company will utilize the unique properties of its MVA-BN platform technology and expects to continue the effort with DOD on the critical project, Chaplin noted.  

Source Credits –http://www.bavarian-nordic.com/investor/news/news.aspx?news=5768



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

US buys all of the global supply of Gilead’s COVID-19 drug remdesivir
US buys all of the global supply of Gilead’s COVID-19 drug remdesivir
By Pankaj Singh

While top-notch companies are racing to develop a vaccine for COVID-19, it looks like the United States has secured almost all of the world’s supply of interim drug remdesivir to treat patients with COVID-19.

...

Potential COVID-19 vaccine by Bharat Biotech to enter clinical trials
Potential COVID-19 vaccine by Bharat Biotech to enter clinical trials
By Pankaj Singh

Bharat Biotech International, a leading Indian biotechnology company, has reportedly announced that its potential coronavirus vaccine, Covaxin, has received Drug Controller General of India (DCGI) approval to start hum...

Seattle Genetics reveals positive data from tisotumab vedotin trial
Seattle Genetics reveals positive data from tisotumab vedotin trial
By Pankaj Singh

Seattle Genetics, Inc., a renowned biotechnology firm that focuses on developing antibody-based cancer treatments, has recently revealed positive topline data from its Phase 2 clinical trial (innovaTV 204) assessing ti...